In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter

被引:72
作者
Dwyer, RM
Bergert, ER
O'Connor, MK
Gendler, SJ
Morris, JC
机构
[1] Mayo Clin & Mayo Fdn, Dept Endocrinol & Internal Med, Dept Endocrinol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Nucl Med, Rochester, MN 55905 USA
[3] Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Scottsdale, AZ USA
关键词
D O I
10.1158/1078-0432.CCR-04-1636
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Expression of the sodium iodide symporter (NIS) in the thyroid gland provides for effective imaging and treatment of thyroid cancer using radiolabeled iodide. Transfer of NIS into other tumors would expand the utility of this treatment to tumors of nonthyroid origin. MUC1 is a transmembrane glycoprotein that is overexpressed in many tumor types, including breast, pancreatic, and ovarian. The aim of this study was to create a construct containing NIS under the control of the MUC1 promoter to target expression specifically to MUC1-positive breast cancer cells. Experimental Design: A replication-deficient adenoviral construct was created containing the MUC1 promoter followed by the human NIS gene. Iodide uptake assays, Western blot, and immunohistochemistry were used to confirm NIS expression and function. Breast cancer xenografts in mice were infected with Ad5/MUC1/NIS and then imaged and treated using radioiodide. Results: A 58-fold increase in iodide uptake was observed in infected MUC1-positive T47D cells with no significant increase observed in MUC1-negative MDA-MB-231 cells or in cells infected with the control virus. The in vivo study yielded clear images of Ad/MUC1/NIS-infected tumor xenografts using I-123. Administration of a therapeutic dose of I-131 resulted in an 83% reduction in tumor volume, whereas control tumors continued to increase in size (P < 0.01). Conclusions: These results show that the MUC1 promoter is capable of directing efficient and selective expression of the NIS gene in MUC1-positive breast tumor cells. This could potentially have applications for both imaging and therapy in a range of MUC1-positive tumor types.
引用
收藏
页码:1483 / 1489
页数:7
相关论文
共 50 条
[1]   Iodide symporter gene expression in human thyroid tumors [J].
Arturi, F ;
Russo, D ;
Schlumberger, M ;
du Villard, JA ;
Caillou, B ;
Vigneri, P ;
Wicker, R ;
Chiefari, E ;
Suarez, HG ;
Filetti, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07) :2493-2496
[2]  
Block A, 2002, ANTICANCER RES, V22, P3285
[3]  
Boland A, 2000, CANCER RES, V60, P3484
[4]  
Brossart P, 2001, CANCER RES, V61, P6846
[5]   THE IODIDE CONCENTRATING MECHANISM OF THE MAMMARY GLAND [J].
BROWNGRANT, K .
JOURNAL OF PHYSIOLOGY-LONDON, 1957, 135 (03) :644-654
[6]   Na+/I- symporter distribution in human thyroid tissues:: An immunohistochemical study [J].
Caillou, B ;
Troalen, F ;
Baudin, E ;
Talbot, M ;
Filetti, S ;
Schlumberger, M ;
Bidart, JM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :4102-4106
[7]   IODIDE TRANSPORT IN THE THYROID-GLAND [J].
CARRASCO, N .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1154 (01) :65-82
[8]   Development of monoclonal antibodies against the human sodium iodide symporter: Immunohistochemical characterization of this protein in thyroid cells [J].
Castro, MR ;
Bergert, ER ;
Beito, TG ;
Mciver, B ;
Goellner, JR ;
Morris, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08) :2957-2962
[9]   Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources [J].
Chen, L ;
Pulsipher, M ;
Chen, DS ;
Sieff, C ;
Elias, A ;
Fine, HA ;
Kufe, DW .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (11) :2539-2548
[10]   Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter [J].
Chen, L ;
Chen, DS ;
Manome, Y ;
Dong, YH ;
Fine, HA ;
Kufe, DW .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2775-2782